
The European Commission (EC) granted marketing authorization for three biosimilars: Amgen’s Pavblu,CuraTeQ Biologics’s Dyrupeg, and Celltrion’s Qoyvolma, between March and June 2025.
More >The European Commission (EC) granted marketing authorization for three biosimilars: Amgen’s Pavblu,CuraTeQ Biologics’s Dyrupeg, and Celltrion’s Qoyvolma, between March and June 2025.
More >